# The Role of Platinum-Based Chemotherapy in the Pathogenesis of Tendinosis in Cancer Patients

## TL;DR

This paper explores how platinum-based chemotherapy might cause tendon problems in cancer patients due to electrolyte imbalances.

## Contribution

It highlights a potential link between platinum chemotherapy, electrolyte imbalances, and tendinosis that has not been thoroughly studied before.

## Key findings

- Platinum-based chemotherapy can cause electrolyte imbalances in cancer patients.
- Electrolyte imbalances may lead to tendon dehydration and collagen synthesis impairment.
- This could result in tendon degeneration in patients on long-term platinum-based treatments.

## Abstract

Currently, there are numerous anti-cancer drugs to prevent the spread of different neoplasms. Patients who depend on these medications as a form of treatment look to hopefully minimize the spread of cancer. However, there are well-known side effects of platinum-based chemotherapies, such as different electrolyte imbalances. These disturbances could possibly lead to the pathogenesis of tendinosis among cancer patients who take long-term platinum-based chemotherapy treatments, something that has not been thoroughly studied and warrants further investigation. Electrolyte disturbances in tendons can lead to dehydration, which can impair collagen synthesis and ultimately lead to tendon degeneration among cancer patients who are utilizing these long-term platinum cancer drugs.